Soligenix Unveils Preclinical Data From Filovirus Vaccine Candidates

Soligenix Inc SNGX announced positive preclinical data from its filovirus vaccine candidates, including thermostabilized multivalent vaccines in a single vial platform presentation.
Data from non-human primates (NHP) demonstrated efficacy.
Collaborators at the University of Hawaiʻi at Mānoa (UHM) describe the potent efficacy of vaccine candidates protecting against three filoviruses, Zaire ebolavirus, Sudan ebolavirus, and Marburg Marburgvirus.
These vaccine candidates contain highly purified protein antigens combined with the novel CoVaccine HT adjuvant in monovalent (single antigen) and bivalent (two antigens) formulations.
Efforts to formulate all three antigens and adjuvant into a thermostable single-vial vaccine platform have been shown to protect 75% of vaccinated NHPs against subsequent Sudan ebolavirus challenge.
Price Action: SNGX shares are up 4.79% at $0.94 during the market session on the last check Wednesday.